Publications
Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. KU Leuven Ghent University
Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy Vrije Universiteit Brussel KU Leuven
Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARC021/TH CR-406) KU Leuven
Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903) KU Leuven
NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects Vrije Universiteit Brussel University of Antwerp
Tropomyosin receptor kinase (TK) is encoded by the neurotrophic tyrosine receptor kinase genes (NTRK) 1, 2, and 3, whose activation plays an important role in cell cycle proliferation and survival. Fusions of one of these genes can lead to constitutive activation of TRK, which can potentially be oncogenic. NTRK fusions are commonly present in rare histologic tumor types. Among sarcomas, infantile fibrosarcoma shows NTRK fusion in more than ...
MDM2 Amplified Sarcomas: A Literature Review KU Leuven
Immune Checkpoint Inhibitory Therapy in Sarcomas: Is There Light at the End of the Tunnel? Vrije Universiteit Brussel University of Antwerp
Soft tissue and bone sarcomas are a very heterogeneous group of tumors with many subtypes for which diagnosis and treatment remains a very challenging task. On top of that, the treatment choices are limited, and the prognosis of aggressive sarcomas remains poor. Immune checkpoint inhibitors (ICIs) have drawn a lot of attention last years because of their promising response rates and their durable effects. ICIs are currently widely used in the ...